ANDOVER,
Mass., Nov. 26, 2024 /PRNewswire/ -- TransMedics
Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology
company that is transforming organ transplant therapy for patients
with end-stage lung, heart, and liver failure, today announced that
it will host an Investor & Analyst Day in New York City on Tuesday, December 10, 2024, at 10:00 AM ET.
Waleed Hassanein, MD., President
and Chief Executive Officer, and members of the leadership team
will present an overview of TransMedics' growth strategy, clinical
pipeline, and operations.
A live and archived webcast of presentations and Q&A
sessions will be available on the "Investors" section of the
TransMedics website at
https://investors.transmedics.com. Please note management will
only take questions from the live audience during the
question-and-answer session following the formal presentations.
In-person attendance at the event requires advanced
registration. Please email Laine
Morgan at laine@gilmartinir.com by December 4, 2024, for further
information.
About TransMedics Group, Inc.
TransMedics is the
world's leader in portable extracorporeal warm perfusion and
assessment of donor organs for transplantation. Headquartered in
Andover, Massachusetts, the
company was founded to address the unmet need for more and better
organs for transplantation and has developed technologies to
preserve organ quality, assess organ viability prior to transplant,
and potentially increase the utilization of donor organs for the
treatment of end-stage heart, lung, and liver failure.
Investor Contact:
Brian
Johnston
Laine Morgan
332-895-3222
Investors@transmedics.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/transmedics-to-host-investor--analyst-day-on-december-10-2024-302316931.html
SOURCE TransMedics Group, Inc.